SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as its dedicated community relentlessly builds a unique permissionless brand, marked by ongoing real-world product development including Kendu Spice and diverse entertainment initiatives. This bullish, active community is consistently recognized across crypto platforms for its 

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense investor scrutiny following its recent earnings report, with the stock experiencing significant after-hours volatility despite an earnings beat. Community sentiment is largely divided, balancing the long-term strategic potential of the proposed Warner Bros. Discovery acquisition and its associated intellectual property against concerns over a pause in share buybacks and a cautious outlook. Discussions are heavily focused on whether current price levels represent a significant buying opportunity or signal further downside amidst an evolving competitive streaming environment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging on the back of severe cold weather forecasts, including polar vortex threats, driving expectations for increased natural gas demand and significant storage withdrawals across the U.S. and Europe. The community is actively discussing a potential short squeeze amid rallying natural gas futures, though many are also highlighting the commodity's notorious volatility and the potential for a swift reversal.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst significant downward pressure, pushing its RSI to historically oversold levels reminiscent of major market downturns and sparking intense debate among traders. While many in the community point to technical breakdowns and broader geopolitical concerns, others anticipate a sharp rebound ahead of upcoming earnings, citing strong iPhone demand and a strategic AI roadmap. This creates a sharply divided sentiment on whether the current dip is a buying opportunity or signals further downside.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial data for its oral eczema drug, soquelitinib, which showed significant skin improvement and a favorable safety profile, even in patients resistant to other therapies. The community is buzzing about its potential as a game-changer in a large market, leading to speculation about future partnerships or a buyout, though some are anticipating a potential share offering following the rapid appreciation.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending due to a strategic private placement by Medtronic complementing a recent public offering, sparking significant community speculation about potential future upside and acquisition. This excitement is further fueled by the company's recent commencement of its pivotal DurAVR heart valve trial, with many viewing the stock as currently undervalued.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention following its strategic partnership with Noveon Magnetics to establish a domestic U.S. supply chain for rare earth permanent magnets, a move strongly supported by broader geopolitical initiatives to reduce reliance on foreign supply. The community is keenly anticipating the upcoming quarterly results for further insights, viewing Lynas as a crucial player positioned to benefit from the tightening global rare earths market amidst increasing demand and strategic government focus on critical minerals.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing heightened trading activity as the community awaits the anticipated finalization of the TikTok U.S. deal while simultaneously reacting to news of a bondholder lawsuit citing undisclosed AI infrastructure debt. Investors are sharply divided, debating whether Oracle's extensive cloud and AI investments will propel future growth or if its increasing debt burden makes it a significant risk.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is actively trending as the community highlights its strategic moves to dominate rare earth production outside China, including a significant acquisition and an updated feasibility study confirming strong economics for its processing expansion. Investors are discussing this as a transformational step towards securing critical minerals for clean energy and AI, reinforcing U.S. energy independence, though some debate its valuation after a rapid run.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid key strategic announcements, including a significant expansion with HD Hyundai in South Korea and a role in building next-gen AI infrastructure across EMEA. CEO Alex Karp's prominent presence at Davos, highlighting AI-driven efficiency and impact, fuels a strong bullish narrative among some investors. Conversely, the community remains divided on its lofty valuation, with others anticipating pullbacks and monitoring broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evofem Biosciences&nbsp;Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt&nbsp;Companies Targeting Closing in Fourth Quarter of 2024&nbsp;Mountain View, CA., September 24, 2024 —&nbsp;Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target,&nbsp;Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a&nbsp;<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318604913&amp;type=HTML&amp;symbol=EVFM&amp;cdn=aa965ae7d29bd4fb48009ea93f2217c9&amp;companyName=Evofem+Biosciences+Inc.&amp;formType=PRE+14A&amp;dateFiled=2024-09-23">preliminary proxy</a> to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the “Merger Agreement”), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt (“Adifem”), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024.&nbsp;No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.&nbsp;About Evofem Biosciences, Inc.Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexxi.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=Phexxi%26%23174%3B+%28lactic+acid%2C+citric+acid+and+potassium+bitartrate%29&amp;index=1&amp;md5=3e729597ceeb7cf85250cc4e87c1ad26">Phexxi&nbsp;®&nbsp;(lactic acid, citric acid and potassium bitartrate)&nbsp;</a>, is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.In July 2024, Evofem broadened its commercial offering with the acquisition of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solosec.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=2&amp;md5=f57d1d7baa215b526187a6b94e5c1456">SOLOSEC® (secnidazole) 2g oral granules&nbsp;</a>, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose.&nbsp;Follow us on: LinkedIn:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem&amp;index=3&amp;md5=d02dd9371f079a9ddf3d4b4c14e86d11">https://www.linkedin.com/company/evofem</a> Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;index=4&amp;md5=7479074d1930b4c67c3da4c67775fd95">http://www.facebook.com/Evofem</a> X (f/k/a Twitter):&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FEvofem&amp;index=5&amp;md5=27b4287d506408c08aa627eaa266acdc">https://x.com/Evofem</a>Phexxi&nbsp;®&nbsp;and SOLOSEC&nbsp;®&nbsp;are registered trademarks of Evofem Biosciences, Inc.&nbsp;About Aditxt, Inc.Aditxt, Inc.®&nbsp;is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.&nbsp;Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.For more information,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aditxt.com&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=www.aditxt.com&amp;index=4&amp;md5=d821cbe54c4f57eac0b1c374c9688090">www.aditxt.com</a>.Follow us on:LinkedIn:&nbsp;<a href="https://www.linkedin.com/company/aditxt">https://www.linkedin.com/company/aditxt</a>&nbsp; Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;index=6&amp;md5=44180bd3ab05184be51a0d6dec9d979b">https://www.facebook.com/aditxtplatform/</a>&nbsp;Forward-Looking StatementsCertain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&amp;A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.&nbsp;Additional Information and Where to Find ItThis communication may be deemed to be solicitation material in respect of the proposed transactions. In connection with the proposed transactions, a proxy statement of Evofem Biosciences, Inc. and other materials will be filed with the SEC. WE URGE INVESTORS TO READ THE PROXY STATEMENT AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EVOFEM BIOSCIENCES, INC. AND THE PROPOSED TRANSACTIONS. Investors will be able to obtain free copies of the proxy statement (when available) as well as other filed documents containing information about Evofem Biosciences, Inc. on the SEC’s website at http://www.sec.gov. Free copies of Evofem Biosciences’ SEC filings are also available from Evofem Biosciences, Inc., 7770 Regents Road, Suite 113-618, San Diego, California 92122, Attention: Corporate Secretary.&nbsp;Participants in the SolicitationEvofem Biosciences and its executive officers, directors, other members of management, employees and Evofem Biosciences may be deemed, under SEC rules, to be participants in the solicitation of proxies from Evofem Biosciences’ stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of Evofem Biosciences is set forth in its definitive proxy statement for its special meeting. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transactions.&nbsp;ContactAditxt, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mary O’Brien&nbsp;<a href="mailto:Mobrien@aditxt.com">Mobrien@aditxt.com</a>(516) 753-9933

Evofem Biosciences  Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt and Evofem file a preliminary proxy for stockholder approval of their merger, targeting a Q4 2024 closing. The merger aims to expand innovative women’s health solutions.

Aditxt and Evofem Seek Approval for Merger, Closing Expected Q4 2024

Equity

Aditxt and Evofem file for stockholder approval to finalize their merger in Q4 2024. The acquisition will position Evofem as a wholly owned Aditxt subsidiary, enhancing their women’s health portfolio.

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Evofem Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

EVFM
Evofem Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EVFM News

EVFMEvofem Biosciences Inc